Phase 1 Pancreatic Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged between 18 and 70 years old
- People who have locally advanced, spread, or returned pancreatic cancer, where a specific protein called eGR1 is found at certain levels on their tumour cells (confirmed through lab testing of tumour tissue), and whose cancer has not responded to standard treatment, who could not tolerate standard treatment, or who have chosen not to have standard treatment
- People who have at least one tumour that can be measured on a scan, according to standard measurement guidelines
- People who have not received any cancer treatment for at least 4 weeks before joining
- People whose general health and ability to carry out daily activities falls within an acceptable range on a standard medical scale (confirm with trial site)
- People whose life expectancy is estimated to be more than 12 weeks
- People whose blood cell counts and kidney function are within the required ranges, as confirmed by blood tests (confirm with trial site for specific numbers)
- People whose liver function and other blood chemistry results are within the required ranges, as confirmed by blood tests (confirm with trial site for specific numbers)
- People who are willing to take part and agree to sign a consent form
Who may not be able to join:
- People whose cancer has spread to the brain or central nervous system
- People who have previously received a type of treatment where immune cells are collected, modified, and put back into the body
- People who have any active, uncontrolled infection, including hepatitis B, hepatitis C, HIV, or syphilis
- People who have received a live vaccine within the past 3 months
- People with a history of a weakened immune system
- People with an active autoimmune disease (where the immune system attacks the body's own tissues)
- People with serious health conditions, including severe breathing problems, serious heart conditions (such as a recent heart attack, unstable chest pain, certain heart rhythm problems, or poor heart pump function), poorly controlled diabetes or other metabolic conditions, or serious gut problems such as significant bleeding, severe diarrhoea, or a blockage requiring medical intervention
- People who may have a severe allergic reaction or other known contraindication to the study drug or its ingredients
- People who are pregnant or breastfeeding
- People with a history of neurological or psychological disorders
- People whom the trial doctors consider unsuitable for the study for other medical reasons
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Zhuan Liao, MD PhD, Changhai Hospital
Phone: +86-13124828854
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Dose-limiting toxicity (DLT); Maximum tolerated dose (MTD); Treatment-emergent adverse event (TEAE) and treatment-emergent serious adverse event (TESAE); Number of participants with abnormal clinical laboratory parameters reported as TEAE; Number of participants with abnormal vital signs reported as TEAE; Number of participants with change from baseline in QT/QTc interval in electrocardiogram
Can't join this trial?
Data last synced from ClinicalTrials.gov: 14 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.